Роль полиморфизма rs1801282 гена PPARG в прогнозировании риска развития нарушений углеводного обмена и выборе тактики лечения

Хасанова К.Б., Медведева М.С., Валеева Е.В., Родыгина Ж.А., Киселева Т.А., Валеева Ф.В. Роль полиморфизма rs1801282 гена PPARG в прогнозировании риска развития нарушений углеводного обмена и выборе тактики лечения. Consilium Medicum. 2022;24(4):266–270. DOI: 10.26442/20751753.2022.4.201672

________________________________________________

Khasanova KB, Medvedeva MS, Valeeva EV, Rodygina ZhA, Kiseleva TA, Valeeva FV. The role of the rs1801282 PPARG polymorphic marker in the prediction and choice of carbohydrate metabolism disorders management: A review. Consilium Medicum. 2022;24(4):266–270. DOI: 10.26442/20751753.2022.4.201672

Читать PDF

Аннотация

Ген PPARG представляет наибольшую ценность в прогнозировании развития нарушений углеводного обмена и ответа пациентов на варианты проводимой терапии. В статье приведены основные сведения о взаимосвязи однонуклеотидного полиморфного локуса rs1801282 гена PPARG с риском развития различных нарушений углеводного обмена, полученные в ходе обзора данных отечественных и зарубежных работ. Несмотря на то что данные литературы относительно ассоциации указанного полиморфизма с развитием метаболических нарушений достаточно противоречивы, большинство исследователей сходятся во мнении в пользу протективного эффекта аллеля G rs1801282 PPARG в отношении риска развития нарушений углеводного обмена. Особый интерес представляет ассоциация rs1801282 PPARG с результатами терапии различными сахароснижающими препаратами, используемыми в лечении предиабета и сахарного диабета 2-го типа. Так, результаты ряда исследований показали, что носители аллеля G rs1801282 PPARG имели лучший ответ на лечение пиоглитазоном с точки зрения снижения уровня глюкозы натощак и гликированного гемоглобина (HbA1c), а также нормализации липидограммы. Взаимосвязь полиморфизма с результатами терапии метформином остается открытым вопросом, требующим дальнейшего изучения.

Ключевые слова: PPARG, полиморфизм, фармакогенетика, углеводный обмен, сахарный диабет 2-го типа, образ жизни

________________________________________________

The PPARG gene has the great value in predicting of carbohydrate metabolism disorders development and the patients’ response to different therapy options. The article presents the information about the association between the single nucleotide polymorphism rs1801282 PPARG and the risk of different carbohydrate metabolism disorders development based on a review of the domestic and foreign researches. Despite that literature data regarding the association of this polymorphism with the development of metabolic disorders differ, most researchers agree that the G-allele of rs1801282 PPARG has the protective effect in relation to the risk of carbohydrate metabolism disorders development. The particular emphasis is placed on the association of rs1801282 PPARG with the results of carbohydrate metabolism disorders management, taking into account the lifestyle changes as well as the intake of oral hypoglycemic drugs used in the treatment of prediabetes and type 2 diabetes. Thus, a number of studies have shown that the G-allele carriers of rs1801282 PPARG had a better response to pioglitazone treatment in the form of lowering of fasting glucose and A1C levels and lipid profile normalization. The association of the polymorphism with the results of therapy with metformin remains an open question that requires further study.

Keywords: PPARG, polymorphism, carbohydrate metabolism, type 2 diabetes, lifestyle, pharmacogenetics

Полный текст

Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью Авторизуйтесь или зарегистрируйтесь.

Список литературы

1. Глобальный доклад по диабету. Женева: Всемирная организация здравоохранения, 2018. Лицензия: CC BY-NC-SA 3.0 IGO [Global report on diabetes. Geneva: World Health Organization, 2018. License: CC BY-NC-SA (in Russian)].
2. Park KS. The search for genetic risk factors of type 2 diabetes mellitus. Diabetes Metab J. 2011;35(1):12-22. DOI:10.4093/dmj.2011.35.1.12
3. Moore AF, Jablonski KA, McAteer JB, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008;57(9):2503-10. DOI:10.2337/db08-0284
4. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434-9. DOI:10.2337/db08-0896
5. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под ред. И.И. Дедова, М.В. Шестаковой, А.Ю. Майорова. 10-й выпуск. Сахарный диабет. 2021;24(S1):221 [Standards of specialized diabetes care. Eds II Dedov, MV Shestakova, AYu Mayorov. 10th edition. Diabetes mellitus. 2021;24(S1):221 (in Russian)]. DOI:10.14341/DM12802
6. Meirhaeghe A, Tanck MWT, Fajas L, et al. Study of a new PPARGamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab. 2005,85(2):140-8. DOI:10.1016/j.ymgme.2005.02.004
7. Montagner A, Rando G, Degueurce G, et al. New insights into the role of PPARs. Prostaglandins Leukot Essent Fatty Acids. 2011;85(5):235-43. DOI:10.1016/j.plefa.2011.04.016
8. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997;18;241(2):270-4. DOI:10.1006/bbrc.1997.7798
9. Frederiksen L, Brødbaek K, Fenger M, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002;87(8):3989-92. DOI:10.1210/jcem.87.8.8732
10. Sarhangi N, Sharifi F, Hashemian L, et al. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. Sci Rep. 2020;10(1):12764. DOI:10.1038/s41598-020-69363-7
11. Wang X, Liu J, Ouyang Y, et al. The association between the Pro12Ala variant in the PPARγ2 gene and type 2 diabetes mellitus and obesity in a Chinese population. PLoS One. 2013;8(8):e71985. DOI:10.1371/journal.pone.0071985
12. Tan GD, Neville MJ, Liverani E, et al. The in vivo effects of the Pro12Ala PPARGamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia. 2006;49(1):158-68. DOI:10.1007/s00125-005-0044-z
13. Ho JS, Germer S, Tam CH, et al. Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract. 2012;97(3):483-91. DOI:10.1016/j.diabres.2012.03.012
14. Бирюкова Е.В. Молекулярно-генетические, гормонально-метаболические и клинические аспекты метаболического синдрома. Автореф. дис. … канд. мед. наук. М. 2009 [Biryukova EV. Molekulyarno-geneticheskie, gormonal'no-metabolicheskie i klinicheskie aspekty metabolicheskogo sindroma. Avtoref. dis. … kand. med. nauk. Moscow. 2009 (in Russian)].
15. Мкртумян А.М., Бирюкова Е.В., Маркина Н.В. Молекулярно-генетические особенности, характер метаболизма глюкозы и функция эндотелия у больных метаболическим синдромом русской популяции. Сахарный диабет. 2008;11(4):26-30 [Mkrtumyan AM, Biryukova EV, Markina NV. Molekulyarno-geneticheskie osobennosti, kharakter metabolizma glyukozy i funktsiya endoteliya u bol'nykh metabolicheskim sindromom russkoy populyatsii. Diabetes mellitus. 2008;11(4):26-30 (in Russian)]. DOI:10.14341/2072-0351-5585
16. Chistiakov DA, Potapov VA, Khodirev DS, et al. The PPARGamma Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects. Diab Vasc Dis Res. 2010;7(1):56-62. DOI:10.1177/1479164109347689
17. Bystrova AA, Ulitina AS, Kim MV, et al. Genetic Risk Factors of Macrovascular Complications in Patients with Type 2 Diabetes. Kardiologiia. 2017;57(2):17-22.
18. Потапов В.А. Поиск генетических маркеров, определяющих предрасположенность к сахарному диабету типа 2. Автореф. дис. … канд. мед. наук. М. 2010 [Potapov VA. Poisk geneticheskikh markerov, opredelyayushchikh predraspolozhennost' k sakharnomu diabetu tipa 2. Avtoref. dis. … kand. med. nauk. Moscow. 2010 (in Russian)].
19. Чернобривцев П.А., Пищулина С.В., Кишеня М.С. Особенности распределения генотипов и аллелей Rs1801282 гена PPARG у больных метаболическим синдромом в Lонецком регионе. Университетская Клиника. 2017;3(24):56-60 [Chernobrivtsev PA, Pishchulina SV, Kishenya MS. Osobennosti raspredeleniya genotipov i allelei Rs1801282 gena PPARG u bol'nykh metabolicheskim sindromom v donetskom regione. Universitetskaya Klinika. 2017;3(24):56-60 (in Russian)].
20. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50(4):891-4. DOI:10.2337/diabetes.50.4.891
21. Galbete C, Toledo E, Martínez-González MA, et al. Pro12Ala variant of the PPARG2 gene increases body mass index: An updated meta-analysis encompassing 49,092 subjects. Obesity (Silver Spring). 2013;21(7):1486-95. DOI:10.1002/oby.20150
22. González Sánchez JL, Serrano Ríos M, Fernández Perez C, et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol. 2002;147(4):495-501. DOI:10.1530/eje.0.1470495
23. Bhatt SP, Misra A, Sharma M, et al. Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther. 2012;14(9):828-34. DOI:10.1089/dia.2011.0277
24. Cole SA, Mitchell BD, Hsueh WC, et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord. 2000;24(4):522-4. DOI:10.1038/sj.ijo.0801210
25. Mansoori A, Amini M, Kolahdooz F, Seyedrezazadeh E. Obesity and Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor-Gamma Gene in Healthy Adults: A Systematic Review and Meta-Analysis. Ann Nutr Metab. 2015;67(2):104-18. DOI:10.1159/000439285
26. Tellechea ML, Aranguren F, Pérez MS, et al. Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men: interaction with smoking status. Circ J. 2009;73(11):2118-24. DOI:10.1253/circj.cj-09-0320
27. Radha V, Vimaleswaran KS, Babu HN, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diabetes Care. 2006;29(5):1046-51. DOI:10.2337/diacare.2951046
28. Hegele RA, Cao H, Harris SB, et al. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab. 2000;85(5):2014-9. DOI:10.1210/jcem.85.5.6610
29. Kilpeläinen TO, Lakka TA, Laaksonen DE, et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc. 2008;40(1):25-33.
DOI:10.1249/mss.0b013e318159d1cd
30. Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes. 2002;51(8):2581-6.
31. Valeeva FV, Medvedeva MS, Khasanova KB, et al. Association of gene polymorphisms with body weight changes in prediabetic patients. Mol Biol Rep. 2022.
DOI:10.1007/s11033-022-07254-y
32. Исакова Ж.Т., Талайбекова Э.T., Жыргалбекова Б.Ж., и др. Межгенные взаимодействия и вклад полиморфных локусов генов KCNJ11, ADIPOQ, оментина, лептина, TCF7L2 и PPARG в развитие сахарного диабета 2-го типа в кыргызской популяции: исследование по типу случай–контроль с использованием MDR-анализа. Проблемы эндокринологии. 2018;64(4):216-25 [Isakova ZhT, Talaibekova ET, Zhyrgalbekova BZh, et al. Gene-gene interaction and the contribution of polymorphic loci of KCNJ11, ADIPOQ, omentin, leptin, TCF7L2 and PPARG genes in the development of type 2 diabetes mellitus in the Kyrgyz population: a case-control genetic association study using MDR-analysis. Problems of Endocrinology. 2018;64(4):216-25 (in Russian)]. DOI:10.14341/probl8344
33. Hashemian L, Sarhangi N, Afshari M, et al. The role of the PPARG (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk. J Diabetes Metab Disord. 2021;20(2):1385-90. DOI:10.1007/s40200-021-00872-6
34. Al-Naemi AH, Ahmad AJ. Is the rs1801282 (G/C) Polymorphism of PPAR – Gamma Gene Associated with T2DM in Iraqi People? Open Access Maced J Med Sci. 2018;6(3):447-55. DOI:10.3889/oamjms.2018.156
35. Wang F, Han XY, Ren Q, et al. Effect of genetic variants in KCNJ11, ABCC8, PPARG and HNF4A loci on the susceptibility of type 2 diabetes in Chinese Han population. Chin Med J (Engl). 2009;122(20):2477-82.
36. Meigs JB, Manning AK, Fox CS, et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genet. 2007;8 Suppl 1(Suppl 1):S16. DOI:10.1186/1471-2350-8-S1-S16
37. Montagnana M, Fava C, Nilsson PM, et al. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals. Diabet Med. 2008;25(8):902-8. DOI:10.1111/j.1464-5491.2008.02510.x
38. Pattanayak AK, Bankura B, Balmiki N, et al. Role of peroxisome proliferator-activated receptor gamma gene polymorphisms in type 2 diabetes mellitus patients of West Bengal, India. J Diabetes Investig. 2014;5(2):188-91. DOI:10.1111/jdi.12130
39. Hotta K, Kitamoto A, Kitamoto T, et al. Association between type 2 diabetes genetic susceptibility loci and visceral and subcutaneous fat area as determined by computed tomography. J Hum Genet. 2012;57(5):305-10. DOI:10.1038/jhg.2012.21
40. Oh EY, Min KM, Chung JH, et al. Significance of Pro12Ala Mutation in Peroxisome Proliferator-Activated Receptor-γ2 in Korean Diabetic and Obese Subjects. J Clin Endocrinol Metab. 2000,85(5):1801-4. DOI:10.1210/jcem.85.5.6499
41. Bakhashab S, Filimban N, Altall RM, et al. The Effect Sizes of PPARγ rs1801282, FTO rs9939609, and MC4R rs2229616 Variants on Type 2 Diabetes Mellitus Risk among the Western Saudi Population: A Cross-Sectional Prospective Study. Genes (Basel). 2020;11(1):98. DOI:10.3390/genes11010098
42. Kruzliak P, Haley AP, Starcevic JN, et al. Polymorphisms of the peroxisome proliferator-activated receptor-γ (rs1801282) and its coactivator-1 (rs8192673) are associated with obesity indexes in subjects with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:42. DOI:10.1186/s12933-015-0197-0
43. Sikhayeva N, Iskakova A, Saigi-Morgui N, et al. Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study. BMC Med Genet. 2017;18(1):76. DOI:10.1186/s12881-017-0443-2
44. Ben Ali S, Ben Yahia F, Sediri Y, et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem. 2009;42(16-17):1642-7. DOI:10.1016/j.clinbiochem.2009.08.019
45. Phani NM, Vohra M, Rajesh S, et al. Implications of critical PPARγ2, ADIPOQ and FTO gene polymorphisms in type 2 diabetes and obesity-mediated susceptibility to type 2 diabetes in an Indian population. Mol Genet Genomics. 2016;291(1):193-204. DOI:10.1007/s00438-015-1097-4
46. Винник Н.И., Куценко Л.А., Куценко Н.Л., и др. Особенности клинической эффективности применения пиоглитазона в комплексной терапии больных с ишемической болезнью сердца на фоне метаболического синдрома. Артериальная гипертензия. 2011;1(15):79-86 [Vinnik NI, Kutsenko LA, Kutsenko NL, et al. Osobennosti klinicheskoi effektivnosti primeneniya pioglitazona v kompleksnoi terapii bol'nykh s ishemicheskoi bolezn'yu serdtsa na fone metabolicheskogo sindroma. Arterial'naya gipertenziya. 2011;1(15):79-86 (in Russian)].
47. Kawaguchi-Suzuki M, Frye RF. Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013;4:147. DOI:10.3389/fphar.2013.00147
48. Hsieh MC, Lin KD, Tien KJ, et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism. 2010;59(8):1139-44. DOI:10.1016/j.metabol.2009.10.030
49. Еременко Т.В., Мациевский Н.А., Ворохобина Н.В., и др. Клинический эффект применения тиазолидиндионов у пациентов с нарушениями углеводного обмена при носительстве полиморфизма rs1801282. Ожирение и метаболизм. 2020;17(2):193-9 [Eremenko TV, Matsievskiy NA, Vorokhobina NV, et al. Clinical effect of thiazolidinediones in subjects with disorders of carbohydrate metabolism in case of polymorphism rs1801282. Obesity and metabolism. 2020;17(2):193-9 (in Russian)]. DOI:10.14341/omet9943
50. Blüher M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003;26(3):825-31. DOI:10.2337/diacare.26.3.825
51. Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH. Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol. 2011;671(1-3):1-6. DOI:10.1016/j.ejphar.2011.09.158
52. Кучер А.Н., Бабушкина Н.П. Роль генетических и средовых факторов в детерминации ответа на метформин. Сахарный диабет. 2021;24(6):571-82 [Kucher АN, Babushkina NP. Role of Genetic and Environmental Factors in Determining the Response to Metformin. Diabetes mellitus. 2021;24(6):571-82 (in Russian)]. DOI:10.14341/DM12744
53. Franks PW, Jablonski KA, Delahanty L, et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2007;50(12):2451-60. DOI:10.1007/s00125-007-0826-6

________________________________________________

1. Global report on diabetes. Geneva: World Health Organization, 2018. License: CC BY-NC-SA (in Russian).
2. Park KS. The search for genetic risk factors of type 2 diabetes mellitus. Diabetes Metab J. 2011;35(1):12-22. DOI:10.4093/dmj.2011.35.1.12
3. Moore AF, Jablonski KA, McAteer JB, et al. Extension of type 2 diabetes genome-wide association scan results in the diabetes prevention program. Diabetes. 2008;57(9):2503-10. DOI:10.2337/db08-0284
4. Zhou K, Donnelly LA, Kimber CH, et al. Reduced-function SLC22A1 polymorphisms encoding organic cation transporter 1 and glycemic response to metformin: a GoDARTS study. Diabetes. 2009;58(6):1434-9. DOI:10.2337/db08-0896
5. Standards of specialized diabetes care. Eds II Dedov, MV Shestakova, AYu Mayorov. 10th edition. Diabetes mellitus. 2021;24(S1):221 (in Russian). DOI:10.14341/DM12802
6. Meirhaeghe A, Tanck MWT, Fajas L, et al. Study of a new PPARGamma2 promoter polymorphism and haplotype analysis in a French population. Mol Genet Metab. 2005,85(2):140-8. DOI:10.1016/j.ymgme.2005.02.004
7. Montagner A, Rando G, Degueurce G, et al. New insights into the role of PPARs. Prostaglandins Leukot Essent Fatty Acids. 2011;85(5):235-43. DOI:10.1016/j.plefa.2011.04.016
8. Yen CJ, Beamer BA, Negri C, et al. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation. Biochem Biophys Res Commun. 1997;18;241(2):270-4. DOI:10.1006/bbrc.1997.7798
9. Frederiksen L, Brødbaek K, Fenger M, et al. Comment: studies of the Pro12Ala polymorphism of the PPAR-gamma gene in the Danish MONICA cohort: homozygosity of the Ala allele confers a decreased risk of the insulin resistance syndrome. J Clin Endocrinol Metab. 2002;87(8):3989-92. DOI:10.1210/jcem.87.8.8732
10. Sarhangi N, Sharifi F, Hashemian L, et al. PPARG (Pro12Ala) genetic variant and risk of T2DM: a systematic review and meta-analysis. Sci Rep. 2020;10(1):12764. DOI:10.1038/s41598-020-69363-7
11. Wang X, Liu J, Ouyang Y, et al. The association between the Pro12Ala variant in the PPARγ2 gene and type 2 diabetes mellitus and obesity in a Chinese population. PLoS One. 2013;8(8):e71985. DOI:10.1371/journal.pone.0071985
12. Tan GD, Neville MJ, Liverani E, et al. The in vivo effects of the Pro12Ala PPARGamma2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank. Diabetologia. 2006;49(1):158-68. DOI:10.1007/s00125-005-0044-z
13. Ho JS, Germer S, Tam CH, et al. Association of the PPARG Pro12Ala polymorphism with type 2 diabetes and incident coronary heart disease in a Hong Kong Chinese population. Diabetes Res Clin Pract. 2012;97(3):483-91. DOI:10.1016/j.diabres.2012.03.012
14. Biryukova EV. Molekulyarno-geneticheskie, gormonal'no-metabolicheskie i klinicheskie aspekty metabolicheskogo sindroma. Avtoref. dis. … kand. med. nauk. Moscow. 2009 (in Russian).
15. Mkrtumyan AM, Biryukova EV, Markina NV. Molekulyarno-geneticheskie osobennosti, kharakter metabolizma glyukozy i funktsiya endoteliya u bol'nykh metabolicheskim sindromom russkoy populyatsii. Diabetes mellitus. 2008;11(4):26-30 (in Russian). DOI:10.14341/2072-0351-5585
16. Chistiakov DA, Potapov VA, Khodirev DS, et al. The PPARGamma Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects. Diab Vasc Dis Res. 2010;7(1):56-62. DOI:10.1177/1479164109347689
17. Bystrova AA, Ulitina AS, Kim MV, et al. Genetic Risk Factors of Macrovascular Complications in Patients with Type 2 Diabetes. Kardiologiia. 2017;57(2):17-22.
18. Potapov VA. Poisk geneticheskikh markerov, opredelyayushchikh predraspolozhennost' k sakharnomu diabetu tipa 2. Avtoref. dis. … kand. med. nauk. Moscow. 2010 (in Russian).
19. Chernobrivtsev PA, Pishchulina SV, Kishenya MS. Osobennosti raspredeleniya genotipov i allelei Rs1801282 gena PPARG u bol'nykh metabolicheskim sindromom v donetskom regione. Universitetskaya Klinika. 2017;3(24):56-60 (in Russian).
20. Mori H, Ikegami H, Kawaguchi Y, et al. The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001;50(4):891-4. DOI:10.2337/diabetes.50.4.891
21. Galbete C, Toledo E, Martínez-González MA, et al. Pro12Ala variant of the PPARG2 gene increases body mass index: An updated meta-analysis encompassing 49,092 subjects. Obesity (Silver Spring). 2013;21(7):1486-95. DOI:10.1002/oby.20150
22. González Sánchez JL, Serrano Ríos M, Fernández Perez C, et al. Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor gamma-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population. Eur J Endocrinol. 2002;147(4):495-501. DOI:10.1530/eje.0.1470495
23. Bhatt SP, Misra A, Sharma M, et al. Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians. Diabetes Technol Ther. 2012;14(9):828-34. DOI:10.1089/dia.2011.0277
24. Cole SA, Mitchell BD, Hsueh WC, et al. The Pro12Ala variant of peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) is associated with measures of obesity in Mexican Americans. Int J Obes Relat Metab Disord. 2000;24(4):522-4. DOI:10.1038/sj.ijo.0801210
25. Mansoori A, Amini M, Kolahdooz F, Seyedrezazadeh E. Obesity and Pro12Ala Polymorphism of Peroxisome Proliferator-Activated Receptor-Gamma Gene in Healthy Adults: A Systematic Review and Meta-Analysis. Ann Nutr Metab. 2015;67(2):104-18. DOI:10.1159/000439285
26. Tellechea ML, Aranguren F, Pérez MS, et al. Pro12Ala polymorphism of the peroxisome proliferatoractivated receptor-gamma gene is associated with metabolic syndrome and surrogate measures of insulin resistance in healthy men: interaction with smoking status. Circ J. 2009;73(11):2118-24. DOI:10.1253/circj.cj-09-0320
27. Radha V, Vimaleswaran KS, Babu HN, et al. Role of genetic polymorphism peroxisome proliferator-activated receptor-gamma2 Pro12Ala on ethnic susceptibility to diabetes in South-Asian and Caucasian subjects: Evidence for heterogeneity. Diabetes Care. 2006;29(5):1046-51. DOI:10.2337/diacare.2951046
28. Hegele RA, Cao H, Harris SB, et al. Peroxisome proliferator-activated receptor-gamma2 P12A and type 2 diabetes in Canadian Oji-Cree. J Clin Endocrinol Metab. 2000;85(5):2014-9. DOI:10.1210/jcem.85.5.6610
29. Kilpeläinen TO, Lakka TA, Laaksonen DE, et al. SNPs in PPARG associate with type 2 diabetes and interact with physical activity. Med Sci Sports Exerc. 2008;40(1):25-33.
DOI:10.1249/mss.0b013e318159d1cd
30. Lindi VI, Uusitupa MI, Lindstrom J, et al. Association of the Pro12Ala polymorphism in the PPAR-gamma2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study. Diabetes. 2002;51(8):2581-6.
31. Valeeva FV, Medvedeva MS, Khasanova KB, et al. Association of gene polymorphisms with body weight changes in prediabetic patients. Mol Biol Rep. 2022.
DOI:10.1007/s11033-022-07254-y
32. Isakova ZhT, Talaibekova ET, Zhyrgalbekova BZh, et al. Gene-gene interaction and the contribution of polymorphic loci of KCNJ11, ADIPOQ, omentin, leptin, TCF7L2 and PPARG genes in the development of type 2 diabetes mellitus in the Kyrgyz population: a case-control genetic association study using MDR-analysis. Problems of Endocrinology. 2018;64(4):216-25 (in Russian). DOI:10.14341/probl8344
33. Hashemian L, Sarhangi N, Afshari M, et al. The role of the PPARG (Pro12Ala) common genetic variant on type 2 diabetes mellitus risk. J Diabetes Metab Disord. 2021;20(2):1385-90. DOI:10.1007/s40200-021-00872-6
34. Al-Naemi AH, Ahmad AJ. Is the rs1801282 (G/C) Polymorphism of PPAR – Gamma Gene Associated with T2DM in Iraqi People? Open Access Maced J Med Sci. 2018;6(3):447-55. DOI:10.3889/oamjms.2018.156
35. Wang F, Han XY, Ren Q, et al. Effect of genetic variants in KCNJ11, ABCC8, PPARG and HNF4A loci on the susceptibility of type 2 diabetes in Chinese Han population. Chin Med J (Engl). 2009;122(20):2477-82.
36. Meigs JB, Manning AK, Fox CS, et al. Genome-wide association with diabetes-related traits in the Framingham Heart Study. BMC Med Genet. 2007;8 Suppl 1(Suppl 1):S16. DOI:10.1186/1471-2350-8-S1-S16
37. Montagnana M, Fava C, Nilsson PM, et al. The Pro12Ala polymorphism of the PPARG gene is not associated with the metabolic syndrome in an urban population of middle-aged Swedish individuals. Diabet Med. 2008;25(8):902-8. DOI:10.1111/j.1464-5491.2008.02510.x
38. Pattanayak AK, Bankura B, Balmiki N, et al. Role of peroxisome proliferator-activated receptor gamma gene polymorphisms in type 2 diabetes mellitus patients of West Bengal, India. J Diabetes Investig. 2014;5(2):188-91. DOI:10.1111/jdi.12130
39. Hotta K, Kitamoto A, Kitamoto T, et al. Association between type 2 diabetes genetic susceptibility loci and visceral and subcutaneous fat area as determined by computed tomography. J Hum Genet. 2012;57(5):305-10. DOI:10.1038/jhg.2012.21
40. Oh EY, Min KM, Chung JH, et al. Significance of Pro12Ala Mutation in Peroxisome Proliferator-Activated Receptor-γ2 in Korean Diabetic and Obese Subjects. J Clin Endocrinol Metab. 2000,85(5):1801-4. DOI:10.1210/jcem.85.5.6499
41. Bakhashab S, Filimban N, Altall RM, et al. The Effect Sizes of PPARγ rs1801282, FTO rs9939609, and MC4R rs2229616 Variants on Type 2 Diabetes Mellitus Risk among the Western Saudi Population: A Cross-Sectional Prospective Study. Genes (Basel). 2020;11(1):98. DOI:10.3390/genes11010098
42. Kruzliak P, Haley AP, Starcevic JN, et al. Polymorphisms of the peroxisome proliferator-activated receptor-γ (rs1801282) and its coactivator-1 (rs8192673) are associated with obesity indexes in subjects with type 2 diabetes mellitus. Cardiovasc Diabetol. 2015;14:42. DOI:10.1186/s12933-015-0197-0
43. Sikhayeva N, Iskakova A, Saigi-Morgui N, et al. Association between 28 single nucleotide polymorphisms and type 2 diabetes mellitus in the Kazakh population: a case-control study. BMC Med Genet. 2017;18(1):76. DOI:10.1186/s12881-017-0443-2
44. Ben Ali S, Ben Yahia F, Sediri Y, et al. Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor gamma-2 gene on obesity risk and leptin levels in a Tunisian population. Clin Biochem. 2009;42(16-17):1642-7. DOI:10.1016/j.clinbiochem.2009.08.019
45. Phani NM, Vohra M, Rajesh S, et al. Implications of critical PPARγ2, ADIPOQ and FTO gene polymorphisms in type 2 diabetes and obesity-mediated susceptibility to type 2 diabetes in an Indian population. Mol Genet Genomics. 2016;291(1):193-204. DOI:10.1007/s00438-015-1097-4
46. Vinnik NI, Kutsenko LA, Kutsenko NL, et al. Osobennosti klinicheskoi effektivnosti primeneniya pioglitazona v kompleksnoi terapii bol'nykh s ishemicheskoi bolezn'yu serdtsa na fone metabolicheskogo sindroma. Arterial'naya gipertenziya. 2011;1(15):79-86 (in Russian).
47. Kawaguchi-Suzuki M, Frye RF. Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol. 2013;4:147. DOI:10.3389/fphar.2013.00147
48. Hsieh MC, Lin KD, Tien KJ, et al. Common polymorphisms of the peroxisome proliferator-activated receptor-gamma (Pro12Ala) and peroxisome proliferator-activated receptor-gamma coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus. Metabolism. 2010;59(8):1139-44. DOI:10.1016/j.metabol.2009.10.030
49. Eremenko TV, Matsievskiy NA, Vorokhobina NV, et al. Clinical effect of thiazolidinediones in subjects with disorders of carbohydrate metabolism in case of polymorphism rs1801282. Obesity and metabolism. 2020;17(2):193-9 (in Russian). DOI:10.14341/omet9943
50. Blüher M, Lübben G, Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003;26(3):825-31. DOI:10.2337/diacare.26.3.825
51. Namvaran F, Azarpira N, Rahimi-Moghaddam P, Dabbaghmanesh MH. Polymorphism of peroxisome proliferator-activated receptor γ (PPARγ) Pro12Ala in the Iranian population: relation with insulin resistance and response to treatment with pioglitazone in type 2 diabetes. Eur J Pharmacol. 2011;671(1-3):1-6. DOI:10.1016/j.ejphar.2011.09.158
52. Kucher АN, Babushkina NP. Role of Genetic and Environmental Factors in Determining the Response to Metformin. Diabetes mellitus. 2021;24(6):571-82 (in Russian). DOI:10.14341/DM12744
53. Franks PW, Jablonski KA, Delahanty L, et al. The Pro12Ala variant at the peroxisome proliferator-activated receptor gamma gene and change in obesity-related traits in the Diabetes Prevention Program. Diabetologia. 2007;50(12):2451-60. DOI:10.1007/s00125-007-0826-6

Авторы

К.Б. Хасанова*, М.С. Медведева, Е.В. Валеева, Ж.А. Родыгина, Т.А. Киселева, Ф.В. Валеева

ФГБОУ ВО «Казанский государственный медицинский университет» Минздрава России, Казань, Россия
*kamilya_khasanova@mail.ru

________________________________________________

Kamilya B. Khasanova*, Maria S. Medvedeva, Elena V. Valeeva, Zhanna A. Rodygina, Tatiana A. Kiseleva, Farida V. Valeeva

Kazan State Medical University, Kazan, Russia
*kamilya_khasanova@mail.ru

Назад к списку

Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.